relapsed acute myeloid leukemia

relapsed acute myeloid leukemia

Exp Content Document Name: topoisomerase inhibitor topotecan treatment of refractory / relapsed acute myeloid leukemia in basic and clinical research Introduction: In recent years, the purpose of / clinical trial confirmed that inhibition of topoisomerase agent topotecan (Topotecan, TPT) and chemotherapy with TPT in refractory / relapsed acute myeloid leukemia (AML) effective. To further prove the mechanism of TPT, the study used MDS acute myeloid leukemia M2 change MUTZ-1 cell line as experimental subjects, preliminary study of the TPT on MUTZ-1 cells proliferation and apoptosis, and cyclophosphamide (CTX) the role of TPT target Topo- mRNA expression levels. In addition, the summary form by the TPT''s CAT (CTX, cytarabine, TPT) in the treatment of refractory / relapsed AML patients with the efficacy and adverse reactions. Method 1. TPT determined by MTT on MUTZ-1 cells in vitro. 2. Annexin measured by flow cytometry, DNA Ladder analysis and electron microscopy evaluation of cell ultrastructure such as TPT on MUTZ-1 cells induced apoptosis. 3. TPT by flow cytometry analysis of MUTZ-1 cell cycle. 4. Semi-quantitative RT-PCR detection of CTX on the Topo- mRNA expression levels. 5. CAT program induction therapy of refractory / relapsed AML 21 cases, calculated response rate, survival, and analysis of relevant .
ObjectiveRecently, results of phase I / II clinical trials have demonstrated that topoisomerase (Topo) I inhibitor Topotecan (TPT) and chemotherapy co

ntaining TPT are effective alternative for treatment of the patients with refractory or relapsed acute myeloid leukemia (AML). To further prove the pharmacologic mechanism of TPT, this study initially explored the effect of TPT on the inhibition of proliferation and proapoptotic activity of MUTZ-1 cells (MDS-RAEB transforming to AML cell line) in vitro, and . Document Name topoisomerase inhibitor topotecan treatment of refractory / relapsed acute myeloid leukemia in basic and clinical research Article NameArticle From Shanghai Institute of Metallurgy; Materials Physics and Chemistry (Professional) PhD thesis in 2000 Keywords Topotecan; MUTZ-1 cells; leukemia; acute; myeloid; refractory; effect; KeywordsTopotecan; MUTZ-1 cell ; leukemia, myeloid, Acute; Refractory; Treatment outcome;
FA in the treatment of refractory / relapsed acute myeloid leukemia observed MAC in the treatment of refractory and relapsed acute myeloid leukemia, 15 cases
HCPT joint program of palliative treatment of recurrent cytarabine, refractory acute myeloid Leukemia
HCPT joint program of palliative treatment of recurrent cytarabine, refractory acute myeloid Leukemia
Medical HEALTH "> Clinical Oncology Summary Programme of sequential bortezomib FLAG treatment of refractory and relapsed acute myeloid leukeagead2.googlesyndication.com/pagead/show_ads.js">

mia in 1 case reRecommended online full-text collection of yellow paper to full-Yang Yuqiong Huang Dongping Liu Shanhao Wannan Medical College Department of Hematology, Yijishan Hospital, Wuhu, Anhui 241001, "Wannan Medical College," 2009 No. 1 28 fast food prizes Report Summary: 1 case report patient, female, 38 years old, because of heart palpitations, chest tightness, 14 months in 2008 admitted to hospital on March 18. Patients in January 2007 palpitations, chest tightness, not treatment. July 2007 symptoms of increased hospital visits, outpatient bone marrow cytology: bone marrow cell proliferation activity, the original cells in ANC15%. Number of pages: 2 page range :77-78 Keywords: FLAG bortezomib subject classification of acute myeloid leukemia: R733.71 [medicine, HEALTH "Onco hematopoietic and lymphoid neoplasms dev leuk acute leukemia] Related Articles: Topics related references (8) coupled literature (5)

Friends Links: Automation Control Blog

www.haluksy.biz www.wiekannmanschnellabnehmen.eu www.celulit.com.pl